Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Rosnilimab, an antibody targeting PD-1.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Peresolimab, an antibody targeting PD-1.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Fiztasovimab, an antibody targeting Human Herpesvirus Glycoprotein B AD-1.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Imvotamab, an antibody targeting CD3E × CD20.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Fazpilodemab, an antibody targeting KLB × FGFR1.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Exidavnemab, an antibody targeting alpha-synuclein.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Ecleralimab, an antibody targeting TSLP.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Camoteskimab, an antibody targeting IL18.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Cifurtilimab, an antibody targeting TNFRSF5.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Eblasakimab, an antibody targeting IL13RA1.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Vensobafusp, an antibody targeting C5.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Verzistobart, an antibody targeting HAVCR2.